8 citations
,
June 2020 in “The Journal of Clinical Endocrinology and Metabolism” This study found that co-administering glucocorticoids with 5α-reductase inhibitors exacerbated the adverse metabolic effects of glucocorticoids in healthy men.
December 2023 in “Journal of the Endocrine Society” In this study, the researchers found that glucocorticoid receptor activation may influence glucose metabolism, with preventive GR antagonist treatment reducing hyperglycemia and restoring glucose tolerance in a PCOS mouse model.
December 2016 in “University of Birmingham Institutional Research Archive (University of Birmingham)” This study found that manipulating 5αR2 activity in human hepatocytes in vitro can regulate lipogenesis, with potential clinical implications for patients taking 5αR inhibitors.
54 citations
,
May 2015 in “Endocrinology” In this study, manipulation of the enzyme 5α-reductase type 2 in human hepatocytes altered lipogenesis, suggesting clinical implications for patients using 5α-reductase inhibitors by affecting glucocorticoid action on hepatic lipid metabolism.
1 citations
,
May 2023 in “Annales d'Endocrinologie” In this study, researchers found that metformin improved glycaemic control and other metabolic parameters in non-diabetic patients on glucocorticoid treatment, also reducing pneumonia risk and hospital admissions, suggesting a potential advantage for routine use in this population.